| Literature DB >> 15657339 |
Scott M Lippman1, Phyllis J Goodman, Eric A Klein, Howard L Parnes, Ian M Thompson, Alan R Kristal, Regina M Santella, Jeffrey L Probstfield, Carol M Moinpour, Demetrius Albanes, Philip R Taylor, Lori M Minasian, Ashraful Hoque, Sarah Moody Thomas, John J Crowley, J Michael Gaziano, Janet L Stanford, Elise D Cook, Neil E Fleshner, Michael M Lieber, Philip J Walther, Fadlo R Khuri, Daniel D Karp, Gary G Schwartz, Leslie G Ford, Charles A Coltman.
Abstract
Prostate cancer continues to be a major health threat, especially among African American men. The Selenium and Vitamin E Cancer Prevention Trial (SELECT), which opened on July 25, 2001, was planned to study possible agents for the prevention of prostate cancer in a population of 32,400 men in the United States, including Puerto Rico, and Canada. SELECT is a phase III randomized, placebo-controlled trial of selenium (200 microg/day from L-selenomethionine) and/or vitamin E (400 IU/day of all rac alpha-tocopheryl acetate) supplementation for a minimum of 7 years (maximum of 12 years) in non-African American men at least 55 years of age and African American men at least 50 years of age. SELECT is a large, simple trial that conforms as closely as possible with community standards of care. This commentary discusses the design problems the SELECT investigators had to resolve in developing the trial, including the role of prostate cancer screening, the best forms and doses of the study agents, and estimation of the event (prostate cancer) rate of men on the placebo arm.Entities:
Mesh：
Substances：
Year: 2005 PMID： 15657339 DOI： 10.1093/jnci/dji009
Source DB: PubMed Journal: J Natl Cancer Inst ISSN： 0027-8874 Impact factor: 13.506